Does the media prefer ETON or ZNTL?

In the previous week, Eton Pharmaceuticals had 11 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 30 mentions for Eton Pharmaceuticals and 19 mentions for Zentalis Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.40 beat Zentalis Pharmaceuticals' score of 0.27 indicating that Eton Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 7 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Neutral Zentalis Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ZNTL or AVLN more profitable?

Avalyn Pharma's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -64.23% -48.16% Avalyn Pharma N/A N/A N/A

Does the media favor ZNTL or AVLN?

In the previous week, Zentalis Pharmaceuticals had 10 more articles in the media than Avalyn Pharma. MarketBeat recorded 19 mentions for Zentalis Pharmaceuticals and 9 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.72 beat Zentalis Pharmaceuticals' score of 0.27 indicating that Avalyn Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avalyn Pharma 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ARDX or ZNTL?

In the previous week, Ardelyx had 2 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 21 mentions for Ardelyx and 19 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.27 beat Ardelyx's score of -0.27 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral Zentalis Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CALT or ZNTL?

Zentalis Pharmaceuticals has a consensus price target of $6.75, indicating a potential upside of 89.61%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Zentalis Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is ZNTL or LBRX more profitable?

LB Pharmaceuticals' return on equity of -25.96% beat Zentalis Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -64.23% -48.16% LB Pharmaceuticals N/A -25.96% -25.03%

Does the media favor ZNTL or LBRX?

In the previous week, Zentalis Pharmaceuticals had 9 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 19 mentions for Zentalis Pharmaceuticals and 10 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.43 beat Zentalis Pharmaceuticals' score of 0.27 indicating that LB Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LB Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Zentalis Pharmaceuticals (ZNTL) Competitors

$3.56 -0.59 (-14.22%)

Closing price 04:00 PM Eastern

Extended Trading

$3.57 +0.01 (+0.28%)

As of 04:54 PM Eastern

Compare

ZNTL vs. ETON, AVLN, ARDX, CALT, and LBRX

Should you buy Zentalis Pharmaceuticals stock or one of its competitors? Zentalis Pharmaceuticals's main competitors and comparable companies include Eton Pharmaceuticals (ETON), Avalyn Pharma (AVLN), Ardelyx (ARDX), Calliditas Therapeutics AB (publ) (CALT), and LB Pharmaceuticals (LBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Zentalis Pharmaceuticals compare to Eton Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

In the previous week, Eton Pharmaceuticals had 11 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 30 mentions for Eton Pharmaceuticals and 19 mentions for Zentalis Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.40 beat Zentalis Pharmaceuticals' score of 0.27 indicating that Eton Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	7 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Neutral
Zentalis Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eton Pharmaceuticals has higher revenue and earnings than Zentalis Pharmaceuticals. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	20.16	-$4.60M	-$0.07	N/A
Zentalis Pharmaceuticals	$67.43M	3.78	-$137.06M	-$1.95	N/A

Zentalis Pharmaceuticals has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Eton Pharmaceuticals' return on equity of -5.68% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%
Zentalis Pharmaceuticals	N/A	-64.23%	-48.16%

Eton Pharmaceuticals presently has a consensus target price of $67.50, indicating a potential upside of 14.68%. Zentalis Pharmaceuticals has a consensus target price of $6.75, indicating a potential upside of 89.61%. Given Zentalis Pharmaceuticals' higher possible upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Eton Pharmaceuticals has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Eton Pharmaceuticals beats Zentalis Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Avalyn Pharma?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Zentalis Pharmaceuticals currently has a consensus price target of $6.75, indicating a potential upside of 89.61%. Avalyn Pharma has a consensus price target of $60.00, indicating a potential upside of 52.87%. Given Zentalis Pharmaceuticals' higher possible upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20

In the previous week, Zentalis Pharmaceuticals had 10 more articles in the media than Avalyn Pharma. MarketBeat recorded 19 mentions for Zentalis Pharmaceuticals and 9 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.72 beat Zentalis Pharmaceuticals' score of 0.27 indicating that Avalyn Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avalyn Pharma	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalyn Pharma has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	3.78	-$137.06M	-$1.95	N/A
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A

Avalyn Pharma's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-64.23%	-48.16%
Avalyn Pharma	N/A	N/A	N/A

Summary

Avalyn Pharma beats Zentalis Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Ardelyx?

Ardelyx (NASDAQ:ARDX) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, Ardelyx had 2 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 21 mentions for Ardelyx and 19 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.27 beat Ardelyx's score of -0.27 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Neutral
Zentalis Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

58.9% of Ardelyx shares are held by institutional investors. 5.3% of Ardelyx shares are held by insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Ardelyx has higher revenue and earnings than Zentalis Pharmaceuticals. Ardelyx is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$450.89M	2.24	-$61.60M	-$0.22	N/A
Zentalis Pharmaceuticals	$67.43M	3.78	-$137.06M	-$1.95	N/A

Zentalis Pharmaceuticals has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. Ardelyx's return on equity of -35.57% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-12.35%	-35.57%	-11.20%
Zentalis Pharmaceuticals	N/A	-64.23%	-48.16%

Ardelyx has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market.

Ardelyx presently has a consensus target price of $15.00, indicating a potential upside of 269.46%. Zentalis Pharmaceuticals has a consensus target price of $6.75, indicating a potential upside of 89.61%. Given Ardelyx's stronger consensus rating and higher probable upside, equities analysts clearly believe Ardelyx is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Ardelyx beats Zentalis Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Zentalis Pharmaceuticals had 19 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 19 mentions for Zentalis Pharmaceuticals and 0 mentions for Calliditas Therapeutics AB (publ). Zentalis Pharmaceuticals' average media sentiment score of 0.27 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Zentalis Pharmaceuticals	Neutral

Zentalis Pharmaceuticals has a consensus price target of $6.75, indicating a potential upside of 89.61%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Zentalis Pharmaceuticals has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Zentalis Pharmaceuticals' return on equity of -64.23% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Zentalis Pharmaceuticals	N/A	-64.23%	-48.16%

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Zentalis Pharmaceuticals. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Zentalis Pharmaceuticals	$67.43M	3.78	-$137.06M	-$1.95	N/A

Summary

Zentalis Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 11 of the 16 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to LB Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and LB Pharmaceuticals (NASDAQ:LBRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

In the previous week, Zentalis Pharmaceuticals had 9 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 19 mentions for Zentalis Pharmaceuticals and 10 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.43 beat Zentalis Pharmaceuticals' score of 0.27 indicating that LB Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LB Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LB Pharmaceuticals' return on equity of -25.96% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-64.23%	-48.16%
LB Pharmaceuticals	N/A	-25.96%	-25.03%

Zentalis Pharmaceuticals currently has a consensus target price of $6.75, indicating a potential upside of 89.61%. LB Pharmaceuticals has a consensus target price of $47.75, indicating a potential downside of 0.06%. Given Zentalis Pharmaceuticals' higher possible upside, equities analysts clearly believe Zentalis Pharmaceuticals is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

LB Pharmaceuticals has lower revenue, but higher earnings than Zentalis Pharmaceuticals. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	3.78	-$137.06M	-$1.95	N/A
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A

Summary

LB Pharmaceuticals beats Zentalis Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Get Zentalis Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZNTL vs. The Competition

Export

Metric	Zentalis Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$255.15M	$11.73B	$6.98B	$13.04B
Dividend Yield	N/A	2.70%	2.58%	10.72%
P/E Ratio	-1.83	781.46	269.56	25.30
Price / Sales	3.78	748.39	598.74	101.64
Price / Cash	N/A	67.45	70.53	50.75
Price / Book	1.19	10.80	13.08	6.33
Net Income	-$137.06M	$2.77B	$3.45B	$347.70M
7 Day Performance	-15.64%	0.15%	1.11%	1.06%
1 Month Performance	-25.37%	0.34%	1.79%	1.03%
1 Year Performance	140.54%	161.53%	67.70%	20.73%

Zentalis Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZNTL Zentalis Pharmaceuticals	2.4653 of 5 stars	$3.56 -14.2%	$6.75 +89.6%	+178.5%	$255.15M	$67.43M	N/A	160	News Coverage Analyst Revision Gap Down High Trading Volume
ETON Eton Pharmaceuticals	3.3472 of 5 stars	$45.14 -2.8%	$52.50 +16.3%	+138.3%	$1.27B	$79.95M	N/A	20	Trending News Earnings Report Analyst Forecast Analyst Revision Gap Up
AVLN Avalyn Pharma	4.3342 of 5 stars	$28.50 -1.0%	$59.00 +107.0%	N/A	$1.26B	N/A	N/A	51	News Coverage Earnings Report Analyst Forecast
ARDX Ardelyx	2.7809 of 5 stars	$4.98 +0.6%	$15.73 +215.8%	-32.0%	$1.22B	$407.32M	N/A	90	Analyst Revision
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZNTL) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zentalis Pharmaceuticals (ZNTL) Competitors

ZNTL vs. ETON, AVLN, ARDX, CALT, and LBRX

How does Zentalis Pharmaceuticals compare to Eton Pharmaceuticals?

Summary

How does Zentalis Pharmaceuticals compare to Avalyn Pharma?

Summary

How does Zentalis Pharmaceuticals compare to Ardelyx?

Summary

How does Zentalis Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Summary

How does Zentalis Pharmaceuticals compare to LB Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL vs. The Competition

Zentalis Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zentalis Pharmaceuticals (ZNTL) Competitors

ZNTL vs. ETON, AVLN, ARDX, CALT, and LBRX

How does Zentalis Pharmaceuticals compare to Eton Pharmaceuticals?

Does the media prefer ETON or ZNTL?

Which has preferable valuation and earnings, ETON or ZNTL?

Is ETON or ZNTL more profitable?

Do analysts prefer ETON or ZNTL?

Which has more volatility and risk, ETON or ZNTL?

Do institutionals & insiders believe in ETON or ZNTL?

Summary

How does Zentalis Pharmaceuticals compare to Avalyn Pharma?

Do analysts rate ZNTL or AVLN?

Does the media favor ZNTL or AVLN?

Which has preferable earnings and valuation, ZNTL or AVLN?

Is ZNTL or AVLN more profitable?

Summary

How does Zentalis Pharmaceuticals compare to Ardelyx?

Does the media prefer ARDX or ZNTL?

Do institutionals & insiders believe in ARDX or ZNTL?

Which has better valuation & earnings, ARDX or ZNTL?

Is ARDX or ZNTL more profitable?

Which has more volatility & risk, ARDX or ZNTL?

Do analysts prefer ARDX or ZNTL?

Summary

How does Zentalis Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Does the media prefer CALT or ZNTL?

Do analysts recommend CALT or ZNTL?

Which has more volatility & risk, CALT or ZNTL?

Do insiders & institutionals believe in CALT or ZNTL?

Is CALT or ZNTL more profitable?

Which has better earnings & valuation, CALT or ZNTL?

Summary

How does Zentalis Pharmaceuticals compare to LB Pharmaceuticals?

Does the media favor ZNTL or LBRX?

Is ZNTL or LBRX more profitable?

Do analysts recommend ZNTL or LBRX?

Which has higher earnings & valuation, ZNTL or LBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL vs. The Competition

Zentalis Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools